Compare Incyte Corporation (INCY) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Newmont Corporation — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 5.3× Incyte Corporation's market cap, and Newmont Corporation pays a 0.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Newmont Corporation for 58 Days on average.
| INCY | NEM | |
|---|---|---|
Market Cap | $22.85B | $121.75B |
Volume | 1,927,029 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $135.14 |
52-Week Low | $83.80 | $78.63 |
Typical Hold Time | 33 Days | 58 Days |
Enterprise Value | $18.35B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Newmont Corporation (NEM) trades at $115.55, up 1.77% with strong fundamental performance including record free cash flow of $5.3B in H1 2026 and three consecutive earnings beats. The stock shows bearish technical signals despite solid valuation metrics with P/E of 14.57 and ROE of 25.53%. Recent news highlights operational improvements and gold price support driving per-share growth initiatives.
NEM presents a compelling value opportunity with strong analyst consensus (75.68% buy rating) and $136.83 price target representing 18% upside. Key risks include gold price volatility and execution of growth projects, but robust cash flow generation and improving margins support long-term shareholder value creation in the current gold market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
